CUTIA-B (02487) announced that its Chief Executive Officer and Executive Director, Zhang Lele, has further increased his shareholding.

18/11/2024

GMT Eight

CUTIA-B (02487) announced that the Board of Directors received a notification from the company's CEO and executive director, Zhang Lele, that he personally purchased a total of 5,200 shares of the company on the open market on November 14, 2024, at a total cost of approximately HK$49,600 (increase in shareholding).

IMMUNEONCO-B(01541): The phase Ib/IIa clinical trial of IMM0306 in combination with lenalidomide for the treatment of chronic lymphocytic leukemia has successfully recruited 27 evaluable patients as of October 26th.

Lizhong Sitong Light Alloys Group (300428.SZ): The adjustment of export tax rebate rates will not have any impact on the company's production and operations.

Contact: contact@gmteight.com

CUTIA-B (02487) announced that its Chief Executive Officer and Executive Director, Zhang Lele, has further increased his shareholding.

RECOMMEND

HK Stock Market Move | Cement stock prices lead gains in October, with cement prices continuing to rise both month-on-month and year-on-year. Institutions say there is still significant room for recovery in cement price-to-book ratios.

Goldman Sachs: Trump's trade policy could lead to "negative spillover effects" Downgrade forecast for Australia's economic growth next year.

Goldman Sachs: maintains a "buy" rating on Alibaba-W (09988) with a target price of HK$131.